Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 09:00 ET | Source: Nordicus Partners Corporation

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.

BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
October 20, 2025 09:00 ET | Source: Nordicus Partners Corporation

Orocidin develops novel cGMP manufacturing process in collaboration with Syngene

The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE)...
October 03, 2025 16:38 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS

BEVERLY HILLS, California, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting...
September 02, 2025 09:53 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market

BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S....
August 07, 2025 09:50 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors

Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in...
April 03, 2025 10:45 ET | Source: Nordicus Partners Corporation

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia

BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
April 02, 2025 11:27 ET | Source: Nordicus Partners Corporation

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs

BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 20, 2025 11:00 ET | Source: Nordicus Partners Corporation

Orocidin and Syngene Partner to Accelerate Biotech Innovation

BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 18, 2025 11:48 ET | Source: Nordicus Partners Corporation

Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study

BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 03, 2025 11:03 ET | Source: Nordicus Partners Corporation

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...